Production Lymphocyte Proliferation and Cytokine Tenascin-C Suppresses Activation-Induced T A 1 A 2 of the Extracellular Matrix Protein The Alternatively Spliced Domain TnFnIII

[1]  P. Vielh,et al.  Opposite regulation of tenascin-C and tenascin-X in MeLiM swine heritable cutaneous malignant melanoma. , 2000, Biochimica et biophysica acta.

[2]  R. Chiquet‐Ehrismann,et al.  Adhesion modulation by antiadhesive molecules of the extracellular matrix. , 2000, Experimental cell research.

[3]  J. Schwarzbauer,et al.  Tenascin-C Suppresses Rho Activation , 2000, The Journal of cell biology.

[4]  P. Jones,et al.  The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[5]  S. Rosenberg Identification of cancer antigens: impact on development of cancer immunotherapies. , 2000, Cancer journal.

[6]  H. M. Geller,et al.  Tenascin-C Contains Domains That Independently Regulate Neurite Outgrowth and Neurite Guidance , 1999, The Journal of Neuroscience.

[7]  S. Schenk,et al.  The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. , 1999, Molecular biology of the cell.

[8]  D. Speiser,et al.  Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. , 1999, Cancer research.

[9]  P. Möller,et al.  Detection of tenascin‐C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases , 1999, International journal of cancer.

[10]  C. Rüegg,et al.  Tenascin‐C inhibits β1 integrin‐dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1 – 5 repeats to fibronectin , 1999, European journal of immunology.

[11]  K Schulten,et al.  Forced unfolding of the fibronectin type III module reveals a tensile molecular recognition switch. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. M. Geller,et al.  Neurite outgrowth promotion by the alternatively spliced region of tenascin-C is influenced by cell-type specific binding. , 1999, Matrix biology : journal of the International Society for Matrix Biology.

[13]  P. Romero,et al.  Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. , 1998, Journal of immunology.

[14]  N. Hiraiwa,et al.  Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. , 1998, The Journal of investigative dermatology.

[15]  D. Hanahan,et al.  Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. , 1998, Cancer research.

[16]  B. McIntyre,et al.  Adenosine Diphosphate (ADP)-Ribosylation of the Guanosine Triphosphatase (GTPase) Rho in Resting Peripheral Blood Human T Lymphocytes Results in Pseudopodial Extension and the Inhibition of  T Cell Activation , 1998, The Journal of experimental medicine.

[17]  C. Geisler,et al.  Two distinct pathways exist for down-regulation of the TCR. , 1998, Journal of immunology.

[18]  Andres F. Oberhauser,et al.  The molecular elasticity of the extracellular matrix protein tenascin , 1998, Nature.

[19]  J. Clarke,et al.  The effect of boundary selection on the stability and folding of the third fibronectin type III domain from human tenascin. , 1998, Biochemistry.

[20]  N. Nakao,et al.  Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. , 1998, The American journal of pathology.

[21]  G. Phillips,et al.  Domains of tenascin involved in glioma migration. , 1998, Journal of cell science.

[22]  H. Erickson,et al.  Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[23]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[24]  G. Chaudhri,et al.  Activation and signal transduction via mitogen‐activated protein (MAP) kinases in T lymphocytes , 1997, Immunology and cell biology.

[25]  T. Boon,et al.  Tumor antigens recognized by T lymphocytes , 1997, International journal of clinical & laboratory research.

[26]  A. Markham,et al.  Human tenascin‐C: Identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae , 1997, International journal of cancer.

[27]  T. Schulthess,et al.  Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. , 1997, Journal of cell science.

[28]  C. Rüegg,et al.  Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. , 1997, Journal of immunology.

[29]  I. Campbell,et al.  Rapid refolding of a proline-rich all-beta-sheet fibronectin type III module. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Langdon,et al.  Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. , 1996, British Journal of Cancer.

[31]  D. Sheppard,et al.  Differential Effects of the Integrins α9β1, αvβ3, and αvβ6 on Cell Proliferative Responses to Tenascin , 1996, The Journal of Biological Chemistry.

[32]  Antonio Lanzavecchia,et al.  T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.

[33]  K. Crossin,et al.  Tenascin: A multifunctional extracellular matrix protein with a restricted distribution in development and disease , 1996, Journal of cellular biochemistry.

[34]  H. Erickson,et al.  Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. , 1996, Molecular biology of the cell.

[35]  E. Spiess,et al.  Tenascin-C contains distinct adhesive, anti-adhesive, and neurite outgrowth promoting sites for neurons , 1996, The Journal of cell biology.

[36]  H. Erickson,et al.  Binding of Tenascin-C to Soluble Fibronectin and Matrix Fibrils * , 1995, The Journal of Biological Chemistry.

[37]  C. Rüegg,et al.  Rapid increase in plasma tenascin‐C concentration after isolated limb perfusion with high‐dose tumor necrosis factor (TNF), interferon gamma (IFNγ) and melphalan for regionally advanced tumors , 1995, International journal of cancer.

[38]  M. Bissell,et al.  Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments. , 1995, Journal of cell science.

[39]  G. Vollmer,et al.  Tenascin‐C in serum: an acute‐phase protein or a carcinoma marker? , 1995, International journal of cancer.

[40]  Y. Okada,et al.  Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases , 1994, FEBS letters.

[41]  H. Erickson,et al.  Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C , 1994, The Journal of cell biology.

[42]  K. Stefansson,et al.  Inhibition of T cell activation by the extracellular matrix protein tenascin. , 1994, Journal of immunology.

[43]  Dan R. Littman,et al.  Signal transduction by lymphocyte antigen receptors , 1994, Cell.

[44]  S. Beck,et al.  Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment , 1993, The Journal of cell biology.

[45]  S. Hirohashi,et al.  Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. , 1993, The American journal of pathology.

[46]  H. Erickson,et al.  Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. , 1993, The Journal of biological chemistry.

[47]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[48]  Y. Soini,et al.  Tenascin in reactive lymph nodes and in malignant lymphomas. , 1992, Pathology, research and practice.

[49]  L. Zardi,et al.  Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1992, International journal of cancer.

[50]  R. Tucker,et al.  Tenascin in bone morphogenesis: expression by osteoblasts and cell type-specific expression of splice variants. , 1992, Journal of cell science.

[51]  L. Zardi,et al.  Comparison of human tenascin expression in normal, simian-virus-40-transformed and tumor-derived cell lines. , 1992, European journal of biochemistry.

[52]  H. Erickson,et al.  Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin [published erratum appears in J Cell Biol 1992 Feb;116(3):833] , 1991, The Journal of cell biology.

[53]  J. Gulcher,et al.  Structure of the human hexabrachion (tenascin) gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Gulcher,et al.  The complete cDNA sequence of human hexabrachion (Tenascin). A multidomain protein containing unique epidermal growth factor repeats. , 1991, The Journal of biological chemistry.

[55]  G. Casari,et al.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. , 1991, Nucleic acids research.

[56]  K. Horgan,et al.  Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. , 1990, Journal of immunology.

[57]  J. Spring,et al.  Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments , 1989, Cell.

[58]  C. Rüegg,et al.  Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Gulcher,et al.  An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[60]  P. Ekblom,et al.  Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions. , 1989, The International journal of developmental biology.

[61]  W. Halfter,et al.  Induction of tenascin in healing wounds , 1988, The Journal of cell biology.

[62]  S. Miescher,et al.  Proliferative and cytolytic potentials of purified human tumor‐infiltrating t lymphocytes. Impaired response to mitogen‐driven stimulation despite T‐cell receptor expression , 1988, International journal of cancer.

[63]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[64]  M. Chiquet,et al.  Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits , 1984, The Journal of cell biology.

[65]  P. Romero,et al.  Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. , 2001, Cancer research.

[66]  俊 日比野 Tenascin Suppresses CD3-mediated T Cell Activation , 1998 .

[67]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[68]  M. Tan,et al.  Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: heterogeneity of splice variants and induction by TGF-beta. , 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[69]  H. Erickson,et al.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. , 1989, Annual review of cell biology.

[70]  M. Kripke Immunologic mechanisms in UV radiation carcinogenesis. , 1981, Advances in cancer research.

[71]  M. Bourdon,et al.  Endothelial cell attachment and spreading on human tenascin is mediated by 2 1 and V 3 integrins , 2022 .